Ocular toxoplasmosis in a pregnant patient presents a distinct clinical challenge. The active posterior uveitis it causes must be treated while accounting for the gestational stage, since drug safety considerations shift substantially across the three trimesters.
This protocol applies to posterior uveitis caused by ocular toxoplasmosis occurring during pregnancy. Treatment decisions in this setting are shaped by the trimester, as the appropriate antiparasitic combination differs between the first, second, and third trimesters.
Management relies on trimester-specific antiparasitic combinations. The regimen and the agents involved change across each trimester — the full structured protocol specifies which combination applies at which stage, along with any co-administered agents required.